echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > A rising star in cancer immunotherapy-γδ T cells

    A rising star in cancer immunotherapy-γδ T cells

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

     

     

    The Dutch biotech startup Lava Therapeutics listed on the Nasdaq with an initial public offering (IPO) of US$100.


    Emerging γδ T cell therapy

    Emerging γδ T cell therapy

    Immune T cells are the main targets of cancer immunotherapy.


    bioon.


    Lava Therapeutics, leader in γδ T cell therapy

    Lava Therapeutics, leader in γδ T cell therapy

    Lava, which focuses on transforming the expertise of the bispecific γδ T cell adaptor into cancer therapy, was established in 2016.


    bioon.


    bioon.


    bioon.


    bioon.


    Xiaobian recommendedConference2021 (12th) Cell Therapy Online International Symposium

    meeting

    http://meeting.


    http://meeting.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.